A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

Respiratory Medicine

Volumn 106, Issue 7, 2012, Pages 970-979

  Donohue, James F ^a   Anzueto, Antonio ^b   Brooks, Jean ^c   Mehta, Rashmi ^d   Kalberg, Christopher ^d   Crater, Glenn ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Anticholinergic; Chronic obstructive pulmonary disease; GSK573719; Long acting bronchodilator; Long acting muscarinic receptor antagonist

Indexed keywords

PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL LABORATORY; CONCUSSION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; ELECTROCARDIOGRAM; EXTRASYSTOLE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOLTER MONITORING; HUMAN; HYPERTENSION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; VITAL SIGN; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84861189477     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.03.012     Document Type: Article

References (16)

1. K.E. Belmonte Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease Proc Am Thorac Soc 4 2005 297 304 (Pubitemid 41566939)
2. B.C. Moulton, and A.D. Fryer Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD Br J Pharmacol 163 2011 44 52
3. N.J. Gross, T.L. Petty, M. Friedman, M.S. Skorodin, G.W. Silvers, and J.F. Donohue Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study Am Rev Respir Dis 139 1989 1188 1191 (Pubitemid 19139843)
4. E.B. Haddad, J.C. Mak, and P.J. Barnes Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping Mol Pharmacol 45 1994 899 907
5. J.A. van Noord, T.A. Bantje, M.E. Eland, L. Korducki, and P.J. Cornelissen A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group Thorax 55 2000 289 294 (Pubitemid 30248798)
6. C. Vogelmeier, C. Verkindre, D. Cheung, J.B. Galdiz, S.Z. Güçlü, and S. Spangenthal Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Pulm Pharmacol Ther 23 2010 438 444
7. P.W. Jones, S.I. Rennard, A. Agusti, P. Chanez, H. Magnussen, and L. Fabbri Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Respir Res 12 2011 55
8. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946 (Pubitemid 38807371)
9. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) (Updated) 2011 http://www.goldcopd.org
10. A. Qaseem, T.J. Wilt, S.E. Weinberger, N.A. Hanania, G. Criner, and T. van der Molen For the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical Practice guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European respiratory Society Ann Intern Med 155 2011 179 191
11. R. Mehta, K. Hardes, A. Cahn, A. Newlands, A. Donald, and A. Preece Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 Inhalation Powder, a new long-acting muscarinic antagonist, in healthy adults Eur Respir J 38 Suppl. 5 2011 613s
12. R. Mehta, D. Kelleher, A. Preece, A. Cahn, and G. Crater Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of inhaled GSK573719, a new long-acting muscarinic antagonist (LAMA), in patients with chronic obstructive pulmonary disease (COPD) Eur Respir J 38 Suppl. 5 2011 138s
13. D.I. Laine, M.A. Luttman, J.J. Foley, C.J. Dehass, C.J. Kotzer, and M. Salmon The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719A predicts once-daily clinical dosing Eur Respir J 38 Suppl. 5 2011 723s
14. M.R. Littner, J.S. Ilowite, D.P. Tashkin, M. Friedman, C.W. Serby, and S.S. Menjoge Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 1136 1142 (Pubitemid 30243820)
15. G.F. Joos, V.J. Schelfhout, R.A. Pauwels, F. Kanniess, H. Magnussen, and R. Lamarca Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients Respir Med 104 2010 865 872
16. N.J. Gross, E. Co, and M.S. Skorodin Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects Chest 96 1989 984 987 (Pubitemid 19266543)